Organovo reports Q3 EPS (7c) vs. (20c) a year ago Reports Q3 revenue $135K, one estimate $180K. The company said its decrease in revenue from prior year levels reflects declining activity under an existing collaborative agreement and the conclusion of a previous collaborative research agreement during the quarter, partially offset by increasing revenue contributions from three recently signed agreements. Organovo is a development stage company, and does not expect product-based revenue until the commercial release of its liver toxicity assay product, currently planned to be before the end of November.
Organovo announces commercial release of exVive3D liver tissue Organovo Holdings announced the full commercial release of the exVive3D Human Liver Tissue for preclinical drug discovery testing. Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.